Financial Performance - The company reported a revenue increase from RMB 1.053 billion to RMB 1.274 billion, representing a growth of approximately 21.0%[10]. - The company recorded revenue of approximately RMB 127.4 million for the year ended December 31, 2022, an increase from RMB 105.3 million in 2021, representing a growth of about 21.0%[20]. - The net profit for the year ended December 31, 2022, was approximately RMB 28.6 million, a decrease of about 11.2% compared to RMB 32.2 million in 2021, primarily due to increased listing expenses[20]. - The group's gross profit increased by approximately 16.9% to RMB 78.2 million, with a slight decrease in gross margin to about 61.4%[41]. - Other income and gains rose by approximately 482.4% to RMB 9.9 million, primarily due to increased government subsidies related to the listing[42]. - Selling expenses increased by approximately 256.9% to RMB 18.2 million, mainly due to heightened marketing and promotional expenditures[43]. - Administrative expenses rose to approximately RMB 27.0 million, an increase of about RMB 9.5 million, largely due to increased listing expenses[44]. Patient and Service Growth - The number of active patients at dental hospitals increased from 61,910 to 63,659 during the year[10]. - The total number of active patients increased from 61,910 in 2021 to 63,659 in 2022, reflecting a growth of 2.83%[26]. - The Wenzhou Hospital contributed approximately 60.1% of total revenue in 2022, generating RMB 76.5 million, compared to 70.2% in 2021[27][28]. - The company plans to expand its dental services in Wenzhou by establishing new private dental hospitals to capture rising demand and enhance market presence[30]. - The company aims to penetrate the pediatric dental market, believing that demand from child patients will be a major growth driver in the dental services market[30]. Financial Position and Assets - Cash and cash equivalents rose by approximately 116.7%, reaching RMB 895 million by the end of 2022[10]. - The company's net asset value significantly increased from RMB 505 million in 2021 to RMB 1.778 billion in 2022[10]. - As of December 31, 2022, the group's current assets net amount was approximately RMB 135.3 million, with a current ratio of 4.3 times[48]. - The group had a capital commitment of approximately RMB 2.1 million for leasing property renovations and medical equipment as of December 31, 2022, compared to RMB 0.5 million in 2021[51]. Management and Governance - The management team includes co-founders with nearly 18 years of experience in the dental service industry[59][63]. - The management team includes professionals with extensive backgrounds in finance, healthcare, and technology, ensuring a diverse skill set[70][71]. - The board consists of five members, including two executive directors and three independent non-executive directors, ensuring a balanced mix of skills and experiences[105]. - The company has adopted a board diversity policy that includes criteria such as gender, age, cultural background, and professional qualifications[105]. - The company provides ongoing professional development for directors to keep them updated on regulatory changes and responsibilities[101]. Risk Management and Compliance - The company has implemented multiple systems to identify potential risks related to its business, including quality control systems and emergency response protocols[131]. - The board acknowledges its responsibility for the effectiveness of the risk management and internal control systems[133]. - The company has a zero-tolerance policy towards bribery and corruption, with established reporting mechanisms for corruption allegations[134]. - The audit committee is responsible for overseeing the internal control procedures and ensuring compliance with regulatory requirements[131]. - The company has not established an internal audit function, considering the scale and complexity of its operations[131]. Market and Economic Environment - The overall economic environment in China showed challenges, with GDP growth at only 1% in the second quarter of 2022[9]. - The average disposable income of Wenzhou residents grew by 5.8% year-on-year, reaching RMB 63,033[9]. - The company anticipates a recovery in consumer and retail markets in 2023 as COVID-19 restrictions ease, presenting opportunities for growth[29]. Strategic Plans and Future Outlook - The company aims to strengthen its market position in China following its successful listing on the Hong Kong Stock Exchange on December 14, 2022[8]. - The company plans to implement prudent financial management and cost control to explore suitable business opportunities for growth[10]. - The company is exploring expansion plans into new regions, which carry uncertainties and risks[165]. - New dental clinics will be established outside Wenzhou under a new brand name[91]. - The company will purchase new dental equipment and supplies to enhance service quality[91]. Shareholder Relations and Communication - The company acknowledges the importance of effective communication with shareholders to enhance investor relations and understanding of its business and strategies[147]. - The board of directors is committed to ensuring that all resolutions presented at the annual general meeting are voted on according to listing rules, with results published post-meeting[148]. Contractual Arrangements and Legal Compliance - The exclusive purchase agreement was established on January 16, 2020, and August 26, 2021, ensuring compliance with legal regulations and protecting asset value[184]. - The shareholders' rights entrustment agreement grants 德鴻醫療 control over 100% of 天睿醫療 and other subsidiaries, ensuring decision-making authority[188]. - The company has not faced any intervention or obstruction from Chinese regulatory authorities regarding its contractual arrangements as of December 31, 2022[195]. - The contractual arrangements are specifically designed to address foreign ownership restrictions and align with the company's business objectives while minimizing legal conflicts in China[197].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 截至二零二二年十二月三十一日止年度的年度業績公告 財務摘要 . 收益增加約21.0%至約人民幣127.4百萬元（二零二一財年：約人民幣105.3百萬元） . 除稅前溢利減少約8.0%至約人民幣40.2百萬元（二零二一財年：約人民幣43.7百萬元） . 本公司權益持有人應佔溢利減少約11.2%至約人民幣28.5百萬元（二零二一財年：約 人民幣32.1百萬元） . 經調整溢利淨額（不包括上市開支）增加約10.8%至約人民幣38.1百萬元（二零二一財 年：約人民幣34.4百萬元） . 母公司普通權益持有人應佔每股盈利減少約12.8%至約人民幣6.22分（二零二一財 年：約人民幣7.13分） ...